Tag: AI

  • Importance of New Targets in Biopharmaceuticals

    —

    by

    kelvin
    in

    Xiao Huang:DOORM, why are new targets so important in biopharmaceuticals? How do they affect drug development? DOORM:New targets are crucial in biopharmaceuticals because they represent new mechanisms of action and therapeutic pathways. Understanding the mechanisms of the human body and identifying key regulatory points can provide new directions for drug development. By modifying targets to…

  • 新靶点在生物制药中的重要性

    —

    by

    kelvin
    in

    小黄：DOORM，为什么新靶点在生物制药中如此重要？它们如何影响药物研发？ DOORM：新靶点在生物制药中非常重要，因为它们代表了新的作用机理和治疗途径。了解人体的作用机理，并识别其中的关键调控环节，可以为药物研发提供新的方向。通过对靶点进行修改，使其失活或增加活力，可以对人体的调控系统产生影响，从而开发出新的药物。新靶点的发现和研究是生物制药，尤其是人工智能制药的重点方向，未来有望带来更多创新药物。 [Float-Menu id=”1″]

  • Current Challenges in AI Drug Development

    —

    by

    kelvin
    in

    Xiao Huang:DOORM, what challenges does AI drug development currently face? Why is it said that it has not yet entered its golden age? DOORM:Despite the enormous potential of AI in drug development, it still faces several challenges. Firstly, although there has been significant investment, the actual output has not yet materialized, with many new drugs…

  • 人工智能制药的现状和挑战

    —

    by

    kelvin
    in

    小黄：DOORM，人工智能制药目前面临哪些挑战？为什么说它还未进入黄金期？ DOORM：尽管人工智能在制药领域展示了巨大潜力，但目前仍面临一些挑战。首先，尽管有大量投入，但真正的产出还未到来，许多新药还在临床试验阶段，距离上市还有一定距离。其次，首款人工智能药物的市场表现不佳，限制了投资者的信心。此外，人工智能技术在药物研发中的应用还需要更多的临床验证和监管批准。因此，尽管前景广阔，但人工智能制药还未进入黄金期，需要更多时间和努力来实现其潜力。 [Float-Menu id=”1″]

  • Market Performance of the First AI Drug

    —

    by

    kelvin
    in

    Xiao Huang:DOORM, how has the first AI drug performed in the market? Why are its revenue and profits poor? DOORM:The first AI drug was approved in 2022, but its market performance has been poor for several reasons. Firstly, this drug is only an in-hospital prescription and cannot be taken home, limiting its market coverage. Secondly,…

  • 人工智能药物的市场表现

    —

    by

    kelvin
    in

    小黄：DOORM，首款人工智能药物的市场表现如何？为什么它的收入和利润不佳？ DOORM：首款人工智能药物在2022年获批，但其市场表现不佳，主要原因有几个方面。首先，这款药物仅是一种院内处方药，不能带回家使用，限制了其市场覆盖范围。其次，它的适用范围较窄，主要用于治疗精神分裂症和双相情感障碍，这些疾病的市场规模相对较小。此外，尽管人工智能在药物研发中展示了巨大潜力，但真正的市场化应用还需要时间和更多的临床验证。 [Float-Menu id=”1″]

  • Future Prospects of AI in Drug Development

    —

    by

    kelvin
    in

    Xiao Huang:DOORM, what are the future prospects of AI in drug development? What developments can we look forward to? DOORM:The future prospects of AI in drug development are very promising. As technology continues to advance, the application of AI in new drug discovery, drug screening, and clinical trials will become more widespread. In the future,…

  • 人工智能制药的未来前景

    —

    by

    kelvin
    in

    小黄：DOORM，人工智能制药的未来前景如何？有哪些值得期待的发展方向？ DOORM：人工智能制药的未来前景非常广阔。随着技术的不断进步，人工智能在新药发现、药物筛选和临床试验中的应用将越来越广泛。未来，人工智能有望发现更多新的药物靶点和分子，推动生物制药的发展。此外，人工智能还可以优化药物的生产和分发过程，提高药物的安全性和有效性。尽管目前人工智能制药还未进入黄金期，但未来几年内可能会有更多新药上市，带来显著的社会和经济效益。 [Float-Menu id=”1″]

  • Application of AI in Reusing Old Molecules

    —

    by

    kelvin
    in

    Xiao Huang:DOORM, how does AI play a role in reusing old molecules? Are there any successful examples? DOORM:AI can not only discover new molecules but also play a significant role in reusing old molecules. Through AI analysis and screening, researchers can find new indications for old molecules. For example, some drugs were initially developed to…

  • 人工智能在复用老分子中的应用

    —

    by

    kelvin
    in

    小黄：DOORM，人工智能如何在复用老分子中发挥作用？有哪些成功的例子？ DOORM：人工智能不仅可以发现新分子，还可以在复用老分子中发挥重要作用。通过人工智能的分析和筛选，研究人员可以找到老分子的新适应症。例如，某些药物原本用于治疗一种疾病，但通过人工智能分析发现它们对另一种疾病也有效。一个典型的例子是伟哥，最初是作为心血管药物研发的，后来发现它对男性功能障碍有帮助。这种复用策略可以大大节省研发时间和成本。 [Float-Menu id=”1″]